ATH 11.1% 0.4¢ alterity therapeutics limited

Forebrain atrophy in early AD, by Masters et al, page-5

  1. 2,789 Posts.
    lightbulb Created with Sketch. 970
    Skint, this paper??: Florian Krismer et al where they found "Brain regions chiefly affected by MSA pathology showed progressive atrophy with annual rates of atrophy for the cerebellar cortex, cerebellar white matter, pons, and putamen of −4.24 ± 6.8%, −8.22 ± 8.8%, −4.67 ± 4.9%, and − 4.25 ± 4.9%, respectively.
    https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29633

    I have not seen this paper earlier but it is important just for the Open study because these patients had had the disease for 4,1 years (mean) and in the Open study for over 3 years. Cerebellar white matter seems to be the best biomarker with an annual atrophy rate of 8%. It should also be measured in the open study.

    Thanks, Skint!
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.4¢
Change
-0.001(11.1%)
Mkt cap ! $20.98M
Open High Low Value Volume
0.5¢ 0.5¢ 0.4¢ $14.55K 3.241M

Buyers (Bids)

No. Vol. Price($)
62 71906262 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 32338803 25
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.